Company Filing History:
1 out of 6 Years Active: 2022-2025
Title: **Hak Jin Chang: Innovator in Cancer Treatment**
Introduction
Hak Jin Chang, based in Harvard, Massachusetts, is a notable inventor recognized for his innovative contributions in the field of pharmacology. With a focused approach toward cancer treatment, he has made significant strides in pharmaceutical research and development.
Latest Patents
Chang holds a patent entitled "Derivatives of piperlongumine and uses thereof." This invention involves a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, which include analogs and pharmaceutically acceptable salts. His work emphasizes processes for preparing these derivatives and formulations containing them, which are essential for their application in cancer treatment.
Career Highlights
Currently, Chang is associated with Auransa Inc., where he contributes to pioneering research that aims to enhance therapeutic options for cancer patients. His expertise and dedication have positioned him as a significant player in the pharmaceutical industry.
Collaborations
Throughout his career, Hak Jin Chang has collaborated with talented individuals such as Andrew Asher Protter and Michael J. Green. These partnerships have fostered a collaborative environment that drives innovation and accelerates the development of new therapeutic solutions.
Conclusion
In conclusion, Hak Jin Chang's work exemplifies the importance of innovation in the fight against cancer. His patented inventions not only represent groundbreaking advancements in medicine but also highlight the collaborative efforts within the scientific community to combat this pervasive disease.